New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially degraded by aldehyde oxidase (AO) in human liver...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmaceutics
Asıl Yazarlar: Kim, Nam Ah, Hong, Sungyoul, Kim, Ki Hyun, Choi, Du Hyung, Kim, Joo Seok, Park, Kyung Eui, Choi, Jun Young, Shin, Young Kee, Jeong, Seong Hoon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7076440/
https://ncbi.nlm.nih.gov/pubmed/32028611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics12020121
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller